Lomustine and Bevacizumab in Progressive Glioblastoma
Authors:
- Wolfgang WickWWWolfgang Wick
- Thierry GorliaTGThierry Gorlia
- Martin BendszusMBMartin Bendszus
- Martin TaphoornMTMartin Taphoorn
- Felix SahmFSFelix Sahm
- Inga HartingIHInga Harting
- Alba A. BrandesABAlba A. Brandes
- Walter TaalWTWalter Taal
- Julien DomontJDJulien Domont
- Ahmed IdbaihAhmed Idbaih
- Mario CamponeMCMario Campone
- Paul M. ClementPCPaul M. Clement
Top Cited Papers
- 16 November 2017
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 377 (20) , 1954-1963
Abstract
Bevacizumab is approved for the treatment of patients with progressive glioblastoma on the basis of uncontrolled data. Data from a phase 2 trial suggested that the addition of bevacizumab to lomustine might improve overall survival as compared with monotherapies. We sought to determine whether the combination would result in longer overall survival than lomustine alone among patients at first progression of glioblastoma. We randomly assigned patients with progression after chemoradiation in a 2:1 ratio to receive lomustine plus bevacizumab (combination group, 288 patients) or lomustine alone (monotherapy group, 149 patients). The methylation status of the promoter of O6-methylguanine–DNA methyltransferase (MGMT) was assessed. Health-related quality of life and neurocognitive function were evaluated at baseline and every 12 weeks. The primary end point of the trial was overall survival. A total of 437 patients underwent randomization. The median number of 6-week treatment cycles was three in the combination group and one in the monotherapy group. With 329 overall survival events (75.3%), the combination therapy did not provide a survival advantage; the median overall survival was 9.1 months (95% confidence interval [CI], 8.1 to 10.1) in the combination group and 8.6 months (95% CI, 7.6 to 10.4) in the monotherapy group (hazard ratio for death, 0.95; 95% CI, 0.74 to 1.21; P=0.65). Locally assessed progression-free survival was 2.7 months longer in the combination group than in the monotherapy group: 4.2 months versus 1.5 months (hazard ratio for disease progression or death, 0.49; 95% CI, 0.39 to 0.61; PMGMT status was prognostic. Despite somewhat prolonged progression-free survival, treatment with lomustine plus bevacizumab did not confer a survival advantage over treatment with lomustine alone in patients with progressive glioblastoma. (Funded by an unrestricted educational grant from F. Hoffmann–La Roche and by the EORTC Cancer Research Fund; EORTC 26101 ClinicalTrials.gov number, NCT01290939; Eudra-CT number, 2010-023218-30.)Keywords
This publication has 25 references indexed in Scilit:
- MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-statusActa Neuropathologica, 2012
- Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteriaNeuro-Oncology, 2011
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patientsEuropean Journal of Cancer, 2010
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent GlioblastomaJournal of Clinical Oncology, 2009
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Beyond the Development of Health-Related Quality-of-Life (HRQOL) Measures: A Checklist for Evaluating HRQOL Outcomes in Cancer Clinical Trials—Does HRQOL Evaluation in Prostate Cancer Research Inform Clinical Decision Making?Journal of Clinical Oncology, 2003
- Construct and Concurrent Validity of the Hopkins Verbal Learning Test – RevisedThe Clinical Neuropsychologist, 1999
- Quality of life assessment in clinical trials—guidelines and a checklist for protocol writers: the U.K. Medical Research Council experienceEuropean Journal of Cancer, 1997
- On the Use of Pocock and Simon's Method for Balancing Treatment Numbers over Prognostic Factors in the Controlled Clinical TrialBiometrics, 1976